ATA Inc. Stock News

atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.

atai Life Sciences (NASDAQ:ATAI) shares tumbled more than 40% in pre-market trading on Friday after the company reported disappointing results from its subsidiary Perception Neuroscience's Phase 2a cl

Shares of Atai Life Sciences NV ATAI, -2.59% tumbled about 44% in premarket trading on Friday after the company said a Phase 2a clinical trial evaluating a ketamine therapy for treatment-resistant dep

Stocks with big upside potential often have significant risks, too.

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

Major positive shifts are happening, but the field faces new headwinds too.

The company specializes in developing psychedelics as therapies.

ATAI is at a value inflection point, it has slimmed its drug discovery pipeline and promises proof of concept data within two years. ATAI has taken on debt to give it a cash runway through to 2025, by

- atai hat den ersten Studienteilnehmer in seiner Phase-1-Studie zu VLS-01 mit ansteigender Einzeldosis (single-ascending dose, SAD) behandelt. Topline-Ergebnisse werden für das erste Halbjahr 2023 e

NEW YORK (USA) und BERLIN (Deutschland), Oct. 05, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) („atai“), ein biopharmazeutisches Unternehmen, das klinische Studien durchführt

- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023.

NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental hea

– Die hundertprozentige Tochtergesellschaft von atai, EmpathBio, hat die Genehmigungen der zentralen Aufsichtsbehörde Medsafe und der Health and Disability Ethics Committees (HDEC) erhalten, um ein